Hélio Elkis
Professor-associado livre-docente do Departamento de Psiquiatria da Faculdade de Medicina da Universidade de São Paulo (FMUSP). Coordenador do Projeto Esquizofrenia (Projesq) do Instituto de Psiquiatria do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (IPq-HC-FMUSP). Pós-doutorado pela Case Western Reserve University, EUA. Membro do International Psychopharmacology Algorithm Project (www.ipap.org)
Mário Rodrigues Louzã
Doutor em medicina pela Universidade de Würzburg, Alemanha. Médico-assistente e coordenador do Projeto Esquizofrenia (Projesq) do Instituto de Psiquiatria do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (IPq-HC-FMUSP)
Abstract:
Background: The second generation antipsychotics represent the great achievement in the treatment of schizophrenia of the last decades. However in the last years some new antipsychotics were synthesized and such new compounds may represent great perspectives for the field of the treatment of schizophrenia. Some of these compounds are in use while others are still on evaluation through clinical trials. Objective: Summarize the current knowledge of new antipsychotics. Methods: PubMed search as well literature provided by the manufactures. Results and Conclusions: We present the main pharmacological characteristics as well as profiles of efficacy, security and tolerability of the following compounds: Asenapine, ACP-103, Bifeprunox, Paliperidone, Long Acting Injectable Risperidone and Sertindole.
Keywords:Antipsychotics, neuroleptics, asenapine, ACP-103, bifeprunox, paliperidone, long acting injectable risperidone, sertindole.